Table 4.
The effect of Ubenimex on the IC50 values and RIs of SGC7901/X cells in the presence or absence of pEGFP-N1-CD13 plasmid for 24h.
| Drugs | SGC7901/X | SGC7901/X+ Ubenimex | SGC7901/X+ Ubenimex/pEGFP-N1-CD13 | |||
|---|---|---|---|---|---|---|
| IC50(ug/ml) | RI | IC50(ug/ml) | RI | IC50(ug/ml) | RI | |
| 5-fluorouracil | 189.1±0.1 | 8.32±0.3 | 68.4±0.3∗∗ | 3.1±0.2∗∗ | 190.4±1.1# | 11.2±0.3# |
|
| ||||||
| Cisplatin | 21.1±0.2 | 17.18±0.1 | 8.76±0.1∗∗ | 7.4±0.2∗∗ | 25.4±1.5# | 16.4±1.2# |
|
| ||||||
| Oxaliplatin | 8.4±0.1 | 20.41±0.2 | 2.99±0.3∗∗ | 7.2±0.1∗∗ | 10.9±1.7# | 21.2±0.1# |
IC50 values and RI were determined by the CCK-8 method. Data are expressed as means ±SD. ∗∗P<0.01 versus 5-fluorouracil, cisplatin, and oxaliplatin without Ubenimex. #P>0.05 versus 5-fluorouracil, oxaliplatin, and cisplatin with the pEGFP-N1-CD13 plasmid stimulation.